Novel therapeutics

Optibrium, a developer of software and artificial intelligence (AI) solutions for drug discovery, recently announced the promotion of Dr Tamsin Mansley to President of its new subsidiary to lead its US-based team and business operations. DDW’s Megan Thomas spoke with Dr Mansley to learn more about what she considers the role of AI in drug […]

DDW was delighted to work with CN Bio on an exclusive event which focused on novel approaches to human lung disease modelling.  The free event took place on 29 March at 3pm.  It covered:  Accelerating the discovery of new therapeutics for treatment of lung injuries using patho/physiology mimicking models. (Speaker Professor Wojciech Chrzanowski, Faculty of […]

The startup company Novel Concepts Medical has announced breakthroughs in its research of Covid-19, which include stopping Covid-19, the Omicron Variant, and long Covid-19 symptoms, including memory loss.   The treatment  Its novel plant-based treatment has resulted in successfully inhibiting the Covid-19 Omicron variant and blocking its connection to human cells. Earlier testing demonstrated:  Stopping the […]

Listen to this article on the DDW Podcast: Dr Tomasz Kostrzewski, Director of Biology at CN Bio Innovations, examines MPS in drug discovery as part of a preclinical toolbox.  Drug development remains slow and costly for the pharmaceutical industry, driven by the financial impact of late-stage failures of drug candidates1. Although our understanding of the molecular […]

Scientists from Queen’s University Belfast have developed a computer-aided data tool that will predict novel sites of binding for potential drugs that are more selective, leading to more effective drug targeting, increasing therapeutic efficacy and reducing side effects. The data tool or protocol will uncover a novel class of compounds – allosteric drugs in G […]

Qingyun Liu, leader of a preclinical development core where researchers can test the effectiveness of large molecule drug candidates for novel cancer treatments, has been awarded an approximately $4 million grant from the Cancer Prevention and Research Institute of Texas (CPRIT).  Liu is Professor of Precision Biomedicine with the Brown Foundation Institute of Molecular Medicine for […]

Hutchmed has been granted Breakthrough Therapy Designation (BTD) by the Center for Drug Evaluation of China’s National Medical Products Administration (NMPA) for amdizalisib (HMPL-689), a highly selective and potent PI3Kδ inhibitor, for the treatment of relapsed or refractory follicular lymphoma (FL), a subtype of non-Hodgkin’s lymphoma (NHL).  Drug candidates with BTD may be considered for conditional approval and […]

An upcoming influx of new therapies into the Pompe disease (PD) pipeline in the next decade is expected by GlobalData to provide a significant boost to the treatment market for this inherited, and often fatal, disorder that can greatly damage the heart and skeletal muscles. In fact, the market is expected to grow at a compound annual […]

News round-up by DDW’s Megan Thomas for 2-6 August This week has seen results released, research continued, and clinical trial phases completed. DDW’s Megan Thomas has rounded up her top five stories showing promise in the drug discovery industry. Cardiac patients receiving nasal gel showed reduction of S. aureus Destiny Pharma, a clinical stage biotechnology […]

Monument Therapeutics has raised £2.6 million in seed funding to spin out of Cambridge Cognition and relocate to Alderley Park, Cheshire. The new company will focus on applying digital biomarkers to neuroscience drug development with a view to matching patient sub-groups with appropriately targeted compounds. Monument Therapeutics applies a novel drug development strategy, leveraging digital […]

PerkinElmer has entered into an agreement to acquire Nexcelom Bioscience for US$260 million. The transaction is expected to close during the second quarter of 2021. Nexcelom provides automated cell counting instruments and aids in the development of cell and gene and immuno-oncology therapies, virology drugs and vaccines. Its expected 2021 revenues are approximately US$40 million. […]

Infex Therapeutics has appointed Pharmaron to help progress its MET-X program which targets urinary tract infections caused by World Health Organisation (WHO) critical-priority resistant Gram-negative bacteria. Pharmaron will manufacture the patented molecule at its plant in Hoddesdon, Hertfordshire. On completion of this stage of the work, MET-X will go through toxicology screening and stability testing, […]

SignalChem Lifesciences, a clinical-stage company who develop novel targeted therapies for oncology, has announced its collaboration with Merck, through a subsidiary, to evaluate the combination of SLC-391, a selective AXL inhibitor developed by SignalChem, with KEYTRUDA (pembrolizumab), Merck’s anti-PD-1 therapy, in patients with advanced non-small cell lung cancer (NSCLC). AXL, a member of the TAM […]

Michael Smyth is Medical Director at Galapagos UK, responsible for launching innovative therapies in the UK to help change the course of inflammatory disease for patients. Having studied medicine at Liverpool University, one of his personal missions is lifelong learning which is reflected in his role to strive for new treatment options that lead to better […]

Fusion Antibodies, pre-clinical antibody discovery, engineering and supply experts, and Queen’s University Belfast, have been awarded a £453,000 grant from Invest Northern Ireland to further expand their COVID-19 targeted research and development efforts. Within the framework of their Northern Ireland Coronavirus Antibody Development Alliance (NICADA), the two organisations will use the funds to accelerate the […]